CRISPR Therapeutics AG Stock Forecast

Stock Price Forecast

According to 25 analysts polled by S&P Global, CRISPR Therapeutics AG stock has a consensus rating of "Buy" and an average price target of $82.24. The average 1-year stock price forecast is 58.21% higher than the current stock price, while the lowest is $33 (-36.51%) and the highest is $291 (+459.83%).

Price Target: $82.24 (+58.21%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$33	$82.24	$76	$291
Change	-36.51%	+58.21%	+46.21%	+459.83%

Analyst Ratings

The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	0	0	0	0	0	0
Buy	10	10	11	11	9	8
Hold	7	4	4	2	4	4
Sell	0	1	1	1	0	0
Strong Sell	0	0	0	0	0	0
Total	17	15	16	14	13	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sami Corwin William Blair	William Blair	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 4, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Buy Maintains $83	Buy	Maintains	$83	+59.68%	May 14, 2026
William Pickering Bernstein	Bernstein	Hold Reiterates $50 → $56	Hold	Reiterates	$50 → $56	+7.73%	May 13, 2026
Jonathan Miller Evercore ISI	Evercore ISI	Buy Maintains $74 → $76	Buy	Maintains	$74 → $76	+46.21%	May 11, 2026
Yigal Nochomovitz Citi	Citi	Buy Reiterates $80 → $82	Buy	Reiterates	$80 → $82	+57.75%	May 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

43.94M

from 3.51M

1,151.95%

from 3.51M

Revenue Next Year

151.68M

from 43.94M

245.17%

from 43.94M

EPS This Year

-4.79

from -6.47

EPS Next Year

-3.86

from -4.79

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	914.96M	1.20M	371.21M	37.31M	3.51M	43.94M
Revenue Growth	127,154.94%	-99.87%	30,885.48%	-89.95%	-90.59%	1,151.95%
Gross Profit	473.22M	-570.70M	-146.38M	-393.59M	-494.78M	39.39M
Gross Margin	51.72%	-47,637.48%	-39.43%	-1,054.80%	-14,096.18%	89.63%
Operating Income	373.53M	-673.16M	-222.54M	-466.57M	-568.32M	-534.92M
Net Income	377.66M	-650.18M	-153.61M	-366.25M	-581.60M	-479.09M
EPS	-	-	-	-	-6.47	-4.79
Free Cash Flow	284.82M	-337.58M	-238.97M	-29.27M	-205.62M	-380.36M
No. Analysts	-	-	-	-	-	20

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	251.2M
Avg	43.9M
Low	n/a

Revenue Growth

Revenue Growth	2026	2027	2028
High	7,057.4%
Avg	1,151.9%
Low	-100.0%

EPS Forecast

EPS	2026	2027	2028
High	-3.35
Avg	-4.79
Low	-6.37

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-